Julia's path to medical innovation began with a solid foundation in bioengineering at UC Berkeley, followed by dual Master's degrees in Bioengineering and Medicine from Stanford University. This unique combination of engineering expertise and medical knowledge positioned her perfectly to identify critical gaps in healthcare technology.

From 2010-2014, she conducted pioneering research at Stanford University School of Medicine's Molecular Imaging Laboratory, developing invaluable insights into medical technology applications and clinical needs. This experience catalyzed her entrepreneurial vision for PuraCath™ Medical, which she founded in 2010 and continues to lead as CEO today.

The Firefly™ System represents a breakthrough in medical device disinfection technology. Using proprietary UV-C light technology, it achieves hospital-grade disinfection in just one second – a dramatic improvement over traditional chemical disinfection methods that can take 10 seconds or longer.

This innovation addresses a critical need in healthcare settings where efficiency, effectiveness, and safety are paramount. The system's versatile platform technology has secured FDA 510(k) clearance for multiple applications, positioning it as a versatile solution across numerous medical specialties.

The Firefly™ System addresses a massive $20B+ global market opportunity across multiple healthcare segments. By providing a faster, more effective, and less expensive disinfection solution, Julia's innovation is positioned to transform standard practices in infection prevention across the medical landscape.

PuraCath's technology is versatile by design, with applications spanning from vascular access and peritoneal dialysis to surgical settings. This scalability allows for significant market penetration while maintaining the core technological advantages that make the Firefly™ System revolutionary.

A robust intellectual property strategy forms the foundation of PuraCath's competitive advantage. Under Julia's leadership, the company has built an impressive patent portfolio comprising 23 filed patents, with 9 already issued in the United States. This comprehensive IP protection creates significant barriers to entry for competitors.

The patents cover the unique aspects of the UV-C disinfection technology, including the proprietary methods for delivering precise light dosage in a remarkably short timeframe. This strategic approach to IP development ensures long-term market exclusivity and positions PuraCath™ for sustained growth and potential licensing opportunities.

The Firefly™ System delivers multiple competitive advantages that position it for widespread adoption. Beyond its remarkable speed advantage, the technology offers significant cost savings – an estimated 54% reduction compared to the standard of care. This powerful combination of superior performance and economic benefits creates a compelling value proposition for healthcare providers.

Additionally, the system's ease of use and versatility make it adaptable to various healthcare settings, from hospitals to outpatient clinics and even home care environments. The technology's ability to deliver professional-grade disinfection with minimal training requirements further enhances its market potential.

As Founder and CEO, Julia Rasooly has demonstrated exceptional leadership in navigating the complex landscape of medical device development, regulatory approval, and commercialization. Her unique background combining bioengineering expertise with medical knowledge enables her to bridge the gap between technical innovation and clinical application.

Under her guidance, PuraCath™ Medical has achieved significant milestones including FDA 510(k) clearance for multiple applications of the Firefly™ System. Julia's vision extends beyond current applications, with ongoing development focused on expanding the UV technology platform into new surgical applications – further extending the potential market impact.